Palatin Technologies, Inc. (LON: 0KF3)
London
· Delayed Price · Currency is GBP · Price in USD
1.000
-0.089 (-8.16%)
Jan 22, 2025, 6:37 PM BST
Palatin Technologies Revenue
Palatin Technologies had revenue of $2.38M USD in the twelve months ending September 30, 2024, down -60.85% year-over-year. In the fiscal year ending June 30, 2024, Palatin Technologies had annual revenue of $4.49M, down -7.49%.
Revenue (ttm)
$2.38M
Revenue Growth
-60.85%
P/S Ratio
n/a
Revenue / Employee
$79.47K
Employees
30
Market Cap
18.28M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.49M | -363.59K | -7.49% |
Jun 30, 2023 | 4.85M | 3.39M | 230.53% |
Jun 30, 2022 | 1.47M | 1.66M | -878.62% |
Jun 30, 2021 | -188.60K | -306.59K | -259.84% |
Jun 30, 2020 | 117.99K | -60.18M | -99.80% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Palatin Technologies News
- 5 weeks ago - Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy - PRNewsWire
- 5 weeks ago - Palatin Technologies announces warrant exercise for ~$3.4M gross proceeds - Seeking Alpha
- 5 weeks ago - Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds - PRNewsWire
- 2 months ago - Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis - PRNewsWire
- 2 months ago - Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 2 months ago - Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results - PRNewsWire
- 2 months ago - Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024 - PRNewsWire
- 2 months ago - Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024 - PRNewsWire